RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (the "Company" or "Science 37"), the clinical research industry's leading MetasiteTM, today ...
RESEARCH TRIANGLE PARK, N.C., April 18, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the appointment of Irena Lambridis as its ...
Transaction values Science 37 at an enterprise value of approximately $1.05 billion at closing Positions Science 37 with a balance sheet of up to $250 million to fund its decentralized trial ...
LOS ANGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Science 37 and Foundation Medicine today announced a collaboration to enable decentralized clinical research in oncology that will optimize recruitment ...
Science 37, a decentralized clinical trial operating system developer, has shared it's going public through a merger with special purpose acquisition company LifeSci Acquisition II Corp. Upon ...
PLAYA VISTA, Calif.--(BUSINESS WIRE)--Science 37, a trailblazing company focused on “site-less” clinical trials, announced today the completion of a Phase 2b study for AOBiome, a clinical-stage life ...
Proprietary technology helps overcome the problem of long travel distances for those taking part in clinical trials. The idea of the “site-less” clinical trial got a boost today as Science 37 signed a ...
Operator Good morning, ladies and gentlemen, and welcome to Science 37’s Earnings Conference Call for the Quarter Ended March 31, 2022. At this time, all participants are in a listen-only mode. We ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results